Glamhive Founder Stephanie Sprangers and Celebrity Stylist Jennifer Rade Announce Digital Fall Style and Beauty Summit
6.11.2020 17:07:00 EET | Business Wire | Press release
Glamhive announced its third online conference to be held on November 14. The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders, from Sarah Jessica Parker's stylist to Kim Kardashian's hairstylist. The innovative leaders will discuss all things fashion, wellness, beauty, and more. Stephanie Sprangers and Jennifer Rade will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201106005072/en/
The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders (Graphic: Mary Kay Inc.)
"I'm excited to co-host the Glamhive LIVE Fall Style and Beauty summit with Stephanie. We're bringing together the most amazing stylists, makeup artists, hairstylists, designers, & entrepreneurs in the world to share everything we've learned—from how we got started to all our tips and tricks on how to have great personal style," said Jennifer Rade, celebrity stylist and costume designer. Jennifer is one of the busiest stylists working today. Her clientele has ranged from A-List stars Angelina Jolie, Abbie Cornish, Cher, and Jenna Fischer, to musicians Lady A, Pink, Marilyn Manson, Dave Matthews, Amy Winehouse, Motley Crue, and Tina Turner. Her work has been featured in many publications, including W, Vanity Fair, Marie Claire, GQ, Esquire, and Harper's Bazaar.
"Glamhive's vision is to make personal styling available to everyone, everywhere, and our digital events are a wonderful extension of that. This year has enabled us to bring our events to everyone, everywhere so that people who are fashion and beauty enthusiasts or work in the industry can learn from the best in the business," said Stephanie Sprangers, Glamhive founder. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature 22 segments with 50-plus speakers. Below is an overview of some of the topics that will be covered by their all-star speaker line-up.
TOPICS:
- Zoom Style: Having Great (and Comfortable) Style
- The Making of a Fashion Stylist
- Foundations First
- How Your Home Environment Impacts Your Mood and Reflects Your Style
- How to Build the Wardrobe of Your Dreams
- 360 Style -- The Interplay of Hair, Makeup, and Wardrobe
- Entrepreneurship -- The Courage to Go For Your Dreams
- Future of the Red Carpet
- French Girl Chic and Our Obsession with Emily in Paris
- Shape Matters -- Love Yourself and Your Shape
- Style Your Health - Boosting Your Energy and Immunity
- Skincare Basics: Coaching Clients on Self-Care
- Iconic Style + How to Make a Statement with Your Style
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr, Keanu Reeves, Dwayne Johnson, Donald Glover, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, Liv Tyler, and more.
CELEBRITY STYLISTS:
Jennifer Rade, Ilaria Urbinati, Erin Walsh, Nicole Chavez, Jeanne Yang, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Sonia Young, Rachel Wirkus, Kesha McCloud
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Danesa Myricks, Andrew Fitzsimons, Daniel Martin, Colleen, Runne, Quinn Murphy, Sheridan Ward, Simedar Jackson, and Mia Santiago
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS
Cindy Eckhert (The Pink Ceiling Fund), Jonathan Sposato (Founder, PicMonkey), Carrie Colbert (Curated Capital), Summer Holl (President, Elyse Walker), Christian Juul Nielsen (Herve Leger | Aknvas), Lucy Aylen (Never Fully Dressed), Dr. Shrereene Idress, Dr. Avanti Kumar Singh
MODERATORS:
Brian Underwood (O the Oprah Magazine), Brooke Jaffe (former Fashion Director, Bloomingdales), Jack Eustace, Nicole Young (E! News), Kibwe Chase Marshall, Co-Founder, The Kelly Initiative), Jezlan Moyet.
Tickets to the conference are $99 for an all-day ticket and include a custom playlist by She-J Nikki Pennie. The presenting sponsor for the Glamhive Digital Fall Style and Beauty Summit is Mary Kay and its Mary Kay Global Design Studio. Other sponsors include NuBra USA, LEO, AKNVAS, NYDJ and more.
For more information, visit www.glamhive.com/upcoming.
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201106005072/en/
Contact information
Stephanie Sprangers, Founder + CEO, Glamhive
stephanie@glamhive.com
+1.206.851.0446
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
